Current Report Filing (8-k)
October 29 2020 - 07:39AM
Edgar (US Regulatory)
false000110068200011006822020-10-292020-10-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
October 29, 2020
Date of Report (Date of earliest event reported)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-15943
|
|
06-1397316
|
|
(State or Other
|
|
(Commission File Number)
|
|
(IRS Employer
|
|
Jurisdiction of Incorporation)
|
|
|
|
Identification No.)
|
251 Ballardvale Street
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices) (Zip Code)
781-222-6000
(Registrant’s
Telephone Number, including Area Code)
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.01 per
share
|
|
CRL
|
|
New York Stock
Exchange
|
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of
1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
ITEM 2.02. Results of Operations and Financial
Condition
The following information shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in
such a filing.
On October 29, 2020, Charles River Laboratories International, Inc.
issued a press release providing financial results for the quarter
ended September 26, 2020.
The press release, attached as an exhibit to this report, includes
"safe harbor" language pursuant to the Private Securities
Litigation Reform Act of 1995, as amended, indicating that certain
statements contained in the press release are "forward-looking"
rather than historic. The press release also states that these and
other risks relating to Charles River are set forth in the
documents filed by Charles River with the Securities and Exchange
Commission.
ITEM 9.01. Financial Statements and Exhibits
(a) Not applicable.
(b) Not applicable.
(c) Exhibits.
99.1
Press release dated October 29, 2020.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
CHARLES RIVER LABORATORIES
INTERNATIONAL,
INC.
|
|
|
|
|
|
Date: October 29, 2020
|
By:
|
/s/ Matthew L. Daniel
|
|
|
|
Matthew L. Daniel, Corporate Senior Vice President,
|
|
|
|
General Counsel, Corporate Secretary & Chief Compliance
Officer
|
EXHIBIT INDEX
4
